UW-Madison Triboelectric Nanogenerator Achieves Tenfold Power Density in Micra-Sized Pacemaker
A battery-free pacemaker powered by an oscillating triboelectric nanogenerator developed at UW-Madison fits inside the Medtronic Micra and produces ten times the power density of earlier nanogenerators. The approach targets the clinical problem of repeated generator replacements in leadless devices. Evidence remains at the preclinical stage and requires chronic in-vivo validation before human use.
The device, described in the August 19 2026 issue of Science Advances, fits inside the existing battery compartment of the Micra intracardiac pacemaker while preserving overall dimensions. Pengfei Chen and Xudong Wang constrained the nanogenerator geometry to match the titanium capsule and optimized material interfaces to harvest mechanical energy from ventricular contraction and relaxation cycles. Bench tests showed sustained output sufficient for standard pacing thresholds.
Current leadless pacemakers dedicate more than half their volume to batteries rated for seven to ten years, after which retrieval from the right ventricle is impractical and additional devices are often implanted. Younger patients therefore face cumulative procedural risks and vascular crowding. The new generator addresses this constraint directly by converting heartbeat motion into electrical energy at power densities previously unattainable in implantable triboelectric systems.
The advance builds on seven years of incremental improvements in flexible electrode interfaces and charge-transfer layers reported by the same group. It also aligns with the 2016 introduction of the Micra platform and subsequent observational data showing reduced infection rates but persistent reintervention needs. Regulatory pathways will require chronic animal implants demonstrating stable output above pacing demand for at least two years before first-in-human studies.
Next milestones include GLP-compliant animal durability testing and integration with existing sensing algorithms. If output remains consistent under varying heart rates and fibrosis conditions, a pivotal trial could begin within five years.
Wang lab: Sustained output above 10 μW will be demonstrated in chronic porcine implants lasting 24 months by 2029.
Sources (2)
- [1]Primary Source(https://www.science.org/doi/10.1126/sciadv.adx1234)
- [2]Supporting Source(https://www.nejm.org/doi/full/10.1056/NEJMra2031593)